Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (607 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2025-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 2.3% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 12 (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: concurrentmripriorulntherapy
  Phrases that lowered it: gastricclinical trialdiseasesthe trialgood
• Phase: 3 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 50 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 75 (lowers risk) · Who can join
• Sponsor's past trials: 43 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (lowers risk) · Drug's FDA history
• Number of arms: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma NCT02301481 · started 2014 · scored riskier than 99% of active trials completed
• A Multicenter Phase II Study of Neoadjuvant Docetaxel, Cisplatin and Capecitabine and Protocolized Surgery in Resectable Gastric Cancer NCT01517009 · started 2008 · scored riskier than 68% of active trials completed
• Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma NCT01286766 · started 2009 · scored riskier than 18% of active trials completed
• Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma NCT00816543 · started 2008 · scored riskier than 33% of active trials completed
• Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer NCT00718913 · started 2008 · scored riskier than 79% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.